MYELOMATCH: Screening Study for Myeloid Cancer Treatment Options

Sponsor: National Cancer Institute (NCI)

Sponsor score: 0
Inactive

ClinicalTrials ID:NCT05564390

Provider View

This study aims to improve treatment options for people with myeloid cancer by using a screening tool to match them with suitable clinical trials or standard treatments. It involves testing bone marrow and blood for specific markers to guide treatment decisions.

Patient Parameters

Program Overview

The MYELOMATCH study is designed to help people with myeloid cancer, such as acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), find the best treatment options. By testing bone marrow and blood samples, doctors can identify specific markers that indicate which treatments might work best. This information helps match patients to clinical trials or standard treatments that target their type of cancer. If no specific trial is available, patients continue with standard care while remaining eligible for future trials.

Description

The MYELOMATCH study involves several steps to help find the best treatment for people with myeloid cancer:

  1. Screening and Reassessment: Patients provide bone marrow and blood samples for testing. These tests look for specific markers that can guide treatment decisions. Results are organized quickly to match patients with suitable clinical trials or standard treatments.

  2. Tier Advancement Pathway (TAP): If no specific trial is available, patients continue with standard care but remain eligible for future trials as new options become available.

  3. Treatment Options: Patients may be assigned to different treatment groups based on their specific cancer type and risk level. These groups test various combinations of chemotherapy and other drugs to find the most effective treatment.

  4. Ongoing Monitoring: Throughout the study, patients undergo regular tests, including bone marrow and blood sample collection, to monitor their response to treatment and adjust as needed.

The study aims to improve treatment outcomes by using personalized approaches based on each patient's unique cancer profile.

Eligibility Criteria

Inclusion Criteria

  • Suspected to have untreated acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS).
  • Must be 18 years or older.
  • No prior anti-cancer therapy for AML or MDS, except for certain allowed medications like hydroxyurea to control white blood cell count.
  • No other active cancer requiring treatment, except for hormonal therapy.
  • Must agree to provide samples for research and participate in specimen banking.
  • Must understand the study and provide informed consent.
  • The study is available at sites with open AML treatment trials or willing to follow the standard care pathway if no trial is available.

Get This Program In Your Inbox

Receive detailed information about this treatment opportunity to review with your healthcare provider.